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Abstract 
The interpretation of case-control studies in which 
blood nutrient levels are examined as etiological 
factors in cancer is complicated by the possibility that 
either the disease or its treatment may alter these 
levels. Circulating levels of selected nutrients were 
examined prior to diagnostic biopsy and compared 
with levels 3 to 4 months after diagnosis among 71 
women with breast cancer and 95 women with benign 
breast disease. Among women with benign breast 
disease or women with breast cancer who were not 
given postsurgical adjuvant drug therapy, levels of a- 
carotene, lycopene, a-tocopherol, cholesterol, and 
triglycerides did not change over time. In contrast, 
women who received chemotherapy had increased 
levels of cholesterol, retinol, and a- and -y-tocopherol , 
and women on antiestrogen therapy showed increased 
levels of triglycerides and a-tocopherol. Overall, the 
concentrations of carotenoids (lycopene, a-carotene, 
and .8-carotene) did not change in breast cancer cases, 
although subgroup analyses showed increased levels of 
.8-carotene among cases not receiving drug treatment 
and decreased levels among those receiving 
antiestrogens. In summary, blood levels of some 
nutrients did not appear to be affected by breast 
cancer or its treatments,  but changes were noted  for 
levels of plasma lipids, tocopherols, retinol, and .8- 
carotene. Those  investigating  the  etiological 
relationshi p between  breast cancer and circulating 
nutrients need to consider these effects in designing 
and  interpreting  epidemiological  studies. 
Introduction 
Much research has been devoted to studying the rela- 
tionship between diet and cancer using case-control 
designs . However, due to limitations in dietary method- 
ology ( 1, 2). particularly the potential for dietary inter- 
views or questionnaires to misclassify individuals accord- 
 
 
 
 
ing to their nutrient intake, alternative indicators of nu- 
tritional status have been sought. 
The use of circulating biochemical indicators of nu- 
tritional status is promising, but the interpretation of 
results in case-control studies is complicated by the 
possibility that either the disease or its treatment may 
alter these levels. Some studies have investigated breast 
cancer by enrolling cases after surgery , potentially during 
treatment or shortly thereafter (3, 4). Thus, questions can 
be raised regarding the etiological relevance of the find- 
ings. Even with study designs that collect blood samples 
months after therapy has been completed, questions can 
be raised regarding the length of time needed for blood 
levels to reflect "usual" status. Blood samples taken upon 
hospital admission (5, 6) also may not represent typical 
levels, since patients are likely to have modified behav- 
iors prior to admission and/or since the tumor may affect 
blood nutrient levels. Thus, methodological studies ana- 
lyzing blood samples at various time periods before and 
after breast cancer diagnosis can be informative. 
Some studies have evaluated the effects of steroid 
therapy . Although the influence of antiestrogen therapy 
on plasma lipids and lipoprotein profiles have been doc- 
umented (7- 14). most studies were limited by small 
numbers and/or lack of assays prior to diagnosis and 
treatment. Little research has been devoted to the effects 
of antiestrogen therapies on plasma micronutrient levels 
or on the effects of cytotoxic treatments on plasma lipids 
and micronutrients. 
To better understand the potential problems of in- 
terpreting circulating biochemical indicators of nutri- 
tional status in case-control studies, we examined the 
levels of selected nutrients before and after the diagnosis 
and treatment of breast cancer . 
Materials and Methods 
Between September 1985 and September 1986, study 
subjects were enrolled from the breast clinic at Roswell 
Park Memorial Institute and from the offices of two 
private surgeons in Buffalo, New York. All participants 
had lived in upstate New York or Pennsylvania for at 
least 1 year. Eligible patients were women 30 to 80 years 
of age who were being evaluated for a breast mass but 
who had no previous history of cancer. All consecutive 
subjects scheduled for diagnostic biopsies, as well as 
those not requiring surgical evaluation, were approached 
for participation in the study, and informed consent was 
obtained. Each subject completed a questionnaire , which 
provided information on dietary intake and breast cancer 
risk factors . Fasting blood samples were obtained both 
before the diagnostic breast biopsy and 3 to 4 months 
later at a follow-up visit or by appointment for those not 
scheduled for a biopsy or return visit. 
 
 
 
 
 
Two-hundred seventy-one patients were requested 
to participate in the overall study, of which 236 (87%) 
consented and completed the questionnaire and 221 
(81%) donated at least the first blood sample . Of these 
participants, 198 (90%) also donated a second blood 
sample 3 to 4 months later. There were no significant 
differences in the participation rates or in the time inter- 
val between the first and second blood samples between 
cases and benign breast disease patients. 
All patients were classified into one of three groups 
based on their clinical examination or pathology reports 
from the breast biopsies: cases (n = 83); benign breast 
disease patients (n = 113); or excluded (n = 40). The 
focus of these analyses were changes in blood nutrient 
levels among benign breast disease patients at average 
risk for breast cancer compared with women who were 
diagnosed with breast cancer. Thus, 40 patients who had 
biopsy reports describing lesions thought to place them 
at increased risk of breast cancer (predominantly of an 
atypical hyperplastic nature) were excluded ( 15, 16). The 
113 benign breast disease patients in this analysis were 
those 79 women who were found to have benign lesions 
not associated with increased risk and 34 women who 
were referred to the specialists because of a suspicious 
mammogram or lump but were determined not to have 
a mass requiring biopsy . Cases were women found to 
have breast cancer (International Classification of Dis- 
eases 9, no. 174) and were classified according to stage 
of disease using standard postsurgical staging forms ( 17). 
The  fasting  blood samples  were  centrifuged,  and 
plasma was preserved in sodium ascorbate ( 10 mg/ml 
plasma) and frozen at -80°C until the end of the study. 
Samples were thawed once for portioning of aliquots and 
once for laboratory analyses. Aliquots from all subjects 
and first  and second  blood draws were analyzed  in a 
random fashion, and all analyses were conducted blind 
to case-control status. Retinal, tocopherols, and carote- 
noids were analyzed by high-pressure liquid chromatog- 
raphy; retinal and tocopherols by a modification (18) of 
a standard method ( 19) and carotenoids by a modifica- 
tion (18) of a new method (20). Triglycerides were ana- 
lyzed using a colorimetric assay (21) and cholesterol by 
a kit method (Sigma Chemical Co., St. Louis, MO). 
All analyses were limited to women with values for 
both blood samples. Statistical analyses were conducted 
using SYSTAT (Systat, 1985 and 1990). Differences in 
means between nutrient levels from bloods obtained 
prior to biopsy (blood no. 1) and 3 to 4 months after 
surgery (blood no. 2) were tested with the paired t test, 
 
 
Table I   Paired analysis of two blood samples taken 3-5 months apart from 
women with benign breast disease 
 
 
Blood  no.  I Blood no. 2 
 
  
Blood marker t units 
Mean (SD) Mean (SD) 
 
 
B-carotene (µg/dli I  1. 1 17.SI 12.7 < 7.01 
a-Catotene (µg/dli 1.4 12.0i ·1.; 1 2 . 1 i 
l ycopene(µg/dl) 2h. I  1 12 41 2>. 1 1 1 2 . 11 
u - Tocopherolµg/dli 1 IS I IS 7BJ 1 367 1'> 1171 
)- Tocoplwrol lµg/dlJ I 7'J 1 1 1 21 190 1 104) 
Retinol   lµg/dli 
Cholesterol  ( mg/dli·' 
Triglyceride'  t mg/di) 
S4.h 112.01 
2 \S I  d! 
<JI\ !Sh) 
SS.9 t 1 2 .Hi 
217 t.SSI 
102 t Shi 
·' n = 95 for cholesterol and n = 91 for all other anyalytes 
 
 
 
Results 
The paired analyses oi the two blood samples in thP 
benign breast disease group are shown in Table 1. Al- 
though no treatments were prpscribedior these patients, 
some may have initiated dietary changes or vitamin sup- 
plement usage, factors not Pvaluated. There wpre no 
significant changes in the plasma levels of the three 
carotenoids ((3-carotene, a-carotene , and lycopene). the 
two tocopherols (a- and )'-tocopherol), retinol, or  the 
two lipids (cholesterol and triglycerides) . 
Paired analyses among breast cancer cases also in- 
dicated no significant differences for the three carote- 
noids, but plasma levels of tocopherols, retinal, chok's- 
terol, and triglyceride showed significant increases in the 
second blood samples drawn from cases (Table 2). Values 
from the first blood sample showed significantly higher 
triglyceride values among casPs compared with benign 
breast disease patients (P = 0.002), whereas )'- and n- 
tocopherol, retinol, and cholesterol concentrations werP 
similar between the two groups. Similar comparisons oi 
the second blood sample showed triglycerides)'-to- 
copherol, and retinol levels were significantly higher 
compared with levels among lwnign breast disease pa- 
tients (P = 0.002, P = 0.001, and P = 0.06, respectively). 
To test differences within treatments, breast cancer 
cases were then stratified according to mutually exclusive 
postsurgical treatment groups . Subjects received either 
no drug treatment , chemotherapy, or tamoxifen. Al- 
though eight patients were treated with  postoperative 
radiation  and  three  with  ovarian  surgery,  all  but  two 
whereas differences between cases and benign breast  
disease patients in nutrient levels in blood no. 1 or blood 
no. 2 were tested with the independent t  test. Blood 
nutrients were log-transformed for t tests but are pre- 
sented as untransformed means. Differences between 
treatments were tested using analysis of covariance con- 
trolling for other potential confounding factors  including 
age, Quetelet's index, dietary fats, and plasma lipids. 
Covariates and nutrient differences were standardized 
for analysis of covariance of treatment effects, and only 
significant (P < 0.05) predictors of the outcome were 
included in the models. Analyses of the change in fat- 
soluble nutrients (retinol, carotenoids, and tocopherols) 
over time controlled for the change in plasma lipids 
during that time. The Quetelet's index and dietary fat 
were measured only at baseline. 
 
 
 
 
 
 
 
 
 
 
 
completed their treatment at least 2 months before the 
second blood sample was drawn and were grouped in 
the category of no drug treatment. In general, the no 
treatment group was composed of earlier stage disease 
(68% in situ and Stage I); the tamoxifen group had slightly 
more severe disease, with positive nodal status and es- 
trogen receptor-positive tumors (87% Stage II); whereas 
the chemotherapy group has the most advanced disease, 
with positive nodal status and estrogen receptor-negative 
tumors (43% Stages Ill-IV). 
There was a marginally significant increase in cho- 
lesterol level in the no drug treatment group (Table 3) 
and a markedly increased cholesterol level in the chemo- 
therapy group. In addition, covariance analysis indicated 
that the change in cholesterol levels over time was dif- 
ferent between cases not on drug therapy and the 
chemotherapy group, after controlling for age and Que- 
telet's index (P = 0.08). This difference over time was 
diminished by controlling for baseline dietary fat intakes, 
since the chemotherapy group had significantly higher 
dietary fat intakes at baseline than did the no treatment 
group. Both the chemotherapy and the no treatment 
groups had significantly greater changes in cholesterol 
over time than did the benign breast disease patients 
after adjusting for age and Quetelet's index (P < 0.01 
and P = 0.02, respectively) . 
Triglyceride levels were significantly increased in the 
tamoxifen group (Table 3) and marginally significantly 
increased in the chemotherapy group. Both of these 
changes over time were also significantly different from 
the change in the no treatment group (P = 0.006 and P 
= 0.042, respectively) and remained significantly differ- 
ent after controlling for age, Quetelet's index, and base- 
line dietary fat intakes. The lack of change in triglyceride 
values in the no treatment cases was similar to that of 
the benign breast disease patients, while the changes 
evident in the tamoxifen and chemotherapy groups were 
significantly different from values for the benign breast 
disease group (P = 0.001 and P = 0.025, respectively) 
after adjustment for age and Quetelet's index. 
The significant increases over time in plasma retinal 
and a- and -y-tocopherol in the breast cancer patients 
(Table 2) but not in the benign breast disease patients 
(Table 1) suggested further investigation by treatment 
groups. Levels of -y-tocopherol rose in all case groups 
and were significantly increased in the no treatment and 
chemotherapy groups (Table 3). Compared with no drug 
treatment, the women with chemotherapy had signifi- 
cantly greater increases in -y-tocopherol over time (P < 
0.001). For a-tocopherol, the increase in the chemother- 
apy group was not significantly greater than in the no 
treatment group,  while the increase in the tamoxifen 
group was significant after controlling for cholesterol 
differences (P = 0.002). Within the chemotherapy group, 
however, the change was significant because of the 
relatively low initial levels. Retinol concentrations within 
treatment groups increased in the no treatment and 
chemotherapy groups but not in the tamoxifen group. 
The larger change in the chemotherapy group was sig- 
nificantly different from the change in the no treatment 
group (P = 0.006). Similar analyses by treatment group 
indicated no differences in a-carotene or lycopene con- 
centrations over time. 11-Carotene, however, decreased 
in the tamoxifen group compared with a slight increase 
in the no treatment group (P = 0.002). These changes 
over time could not be explained by differences in 
plasma lipids, tocopherols, age, or Quetelet's index. In- 
terestingly, both treatment groups had lower mean levels 
in blood 1 compared with the mean concentration in the 
no treatment group. Outliers were noted for several of 
these micronutrients; analyses after the removal of out- 
liers showed results similar to those presented. 
 
 
Discussion 
This study demonstrated significant changes in plasma 
nutrients over a 3-4-month period of time after breast 
cancer diagnosis and surgical treatment, whereas benign 
breast disease patients did not show changes in nutrient 
status over a similar time period. Adjuvant therapy with 
tamoxifen was associated with decreased levels of 11- 
carotene and increased levels of triglycerides and a- 
tocopherol, whereas chemotherapy was associated with 
elevation in levels of cholesterol, -y-tocopherol, and ret- 
inal. Within the group of cases not receiving drug treat- 
ment, there were increases in cholesterol, -y-tocopherol, 
and retinol concentrations after the diagnosis. These 
results suggest that in case-control studies, nutrient val- 
ues in blood samples drawn from cases after surgery and/ 
or treatment may not be accurate  indicators of levels 
before diagnosis. 
Women in the no drug treatment group by definition 
had earlier stage disease than the wo.nen in the treat- 
ment groups. Therefore, comparison of the difference in 
values over time between no drug treatment and treat- 
ment also may be due to the effect of disease progression 
 
 
  
 
 
 
 
during that time period. It is unlikely, however, that 
disease progression within such a short period of time 
would result in such marked changes in nutrient levels. 
Whether due to disease or to treatment, the observed 
changes in nutrient levels after treatment are of meth- 
odological importance. In contrast, it is unknown why 
some nutrient levels changed in the no drug treatment 
group, although we can speculate that there may have 
been life style changes after diagnosis. It remains unclear 
whether blood samples taken at the time of diagnosis are 
atypically low (related to disease or behavior) or whether 
the later blood sample reflects changed behaviors. Fur- 
ther evaluations with sequential blood sampling and eval- 
uation of life style changes in women with breast cancer 
would be worthwhile . 
Substantial effects of breast cancer and/or its treat- 
ment were noted on levels of triglycerides and choles- 
terol. The effect of tamoxifen on plasma triglycerides has 
been noted previously (7- 14), but the moderate effect 
of chemotherapy on plasma triglyceride levels has not 
been previously reported. Cholesterol increased substan- 
tially among women receiving chemotherapy. This was 
especially evident in women with more advanced disease 
who had lower prediagnostic cholesterol levels (data not 
shown). It was not possible to completely separate the 
effect of removal of a more advanced tumor from that of 
chemotherapy and/or from any subsequent dietary 
changes that might have occurred in that group. A pos- 
sible explanation for a direct effect of chemotherapy on 
cholesterol levels, however, involves increased low den- 
sity lipoprotein receptor activity in tumor cells. It has 
been shown that patients with acute leukemia have 
hypocholesterolemia and increased low-density lipopro- 
tein receptor activity in tumor tissue at diagnosis and that 
plasma cholesterol levels increase concurrently with the 
loss of tumor cells during chemotherapy (22, 23). There 
is also suggestive evidence for this mechanism in breast 
tissue (23). We have previously reported lowered cho- 
lesterol levels with stage of disease in this study group 
(24), which is congruent with the findings of hypocholes- 
terolemia at diagnosis observed in case studies (22, 23). 
Although the present study is limited in sample size, 
especially among those with more advanced disease, our 
data suggest that both the disease and chemotherapy 
affect cholesterol levels. 
Although tamoxifen has been reported to be asso- 
ciated with an approximate 10% decrease in total cho- 
lesterol (13, 14) we did not observe such a decrease in 
this study. Adjuvant therapy was not initiated in the 
present study until 4-6 weeks after surgery, which would 
have resulted in a minimum duration of treatment  of 
6-8 weeks at the time of the second blood collection . 
Love and coworkers (11) noted a decrease from baseline 
after 3 months of treatment. Thus, there may have been 
insufficient time for the cholesterol lowering effect of 
tamoxifen to have become evident in our study . 
The increased levels of a-tocopherol (25-28) and 
retinol (27, 28) between the first and second blood 
samples among cases, and especially among women who 
received chemotherapy, could have resulted from die- 
tary changes, initiation of vitamin supplementation, or 
relatively low initial values. Likewise, slight changes in {3- 
carotene in the no drug treatment and tamoxifen groups 
suggest that blood samples drawn after diagnosis may 
not be representative of a subject's usual status. These 
 
data suggest that it may be preferable to obtain 2 sam- 
ples/individual to better estimate status  (29).  For exam- 
ple, in this study the mean {3-carotene values of the two 
blood samples within the tamoxifen and chemotherapy 
groups were lower (8.8 and 8.1 µg/dl, respectively) than 
the means for the no drug treatment ( 14.8 µg/dl)  or 
benign breast disease group ( 13.0 µg/dl).  The  mean of 
two blood samples may generate a more accurate esti- 
mate of usual status, but further work in this area is 
needed. 
The lack of statistical differences in all nutrients 
tested at two time points in the benign breast disease 
patients, and in triglycerides, a-tocopherol, a-carotene, 
lycopene in cases receiving no drug treatment suggests 
that these markers are stable within individuals not on 
drug therapy over a limited  period of time. Therefore, 
epidemiologists may be confident in testing untreated 
cases for some nutrients at 4 or more months after 
diagnosis in case-control studies. However, very few 
cases are likely to be found at the present time without 
adjuvant drug therapies, in contrast to the present study, 
which was conducted prior to the 1988 National Cancer 
Institute Clinical Alert recommending widespread usage 
of tamoxifen adjuvant therapy based on data from the 
Third International Conference on Adjuvant Therapy of 
Primary Breast Cancer (30). 
Since many of the nutrients  investigated were af- 
fected by breast cancer treatments, the interpretation of 
case-control studies of breast cancer should consider the 
timing of the blood collection . Although this study had a 
limited number of subjects in each treatment group, 
potentially important associations were observed . These 
associations should be examined in larger studies. Fur- 
ther investigation with earlier prediagnostic and later 
postdiagnostic or posttreatment samples would assist in 
determining opportune periods for specimen collections. 
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